ClearPoint Neuro, Inc. CLPT
We are a commercial-stage medical device company, incorporated in 1998 as a Delaware corporation, that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. From our inception in 1998, we have deployed significant resources to fund our efforts to develop the foundational capabilities for enabling magnetic resonance imaging ("MRI") guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies we develop. In 2021, our efforts expanded beyond the MRI suite to encompass development and commercialization of neurosurgical device products for the operating room setting, as well as consulting services for pharmaceutical companies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.0M | $31.4M | $24.0M | $20.6M | $16.3M | $12.8M | $11.2M | $7.4M | $7.4M | $5.7M |
| Cost of revenue | $14.3M | $12.3M | $10.3M | $7.0M | $5.2M | $3.7M | $3.9M | $2.4M | $2.9M | $2.6M |
| Gross profit | $22.7M | $19.1M | $13.6M | $13.5M | $11.1M | $9.1M | $7.3M | $4.9M | $4.5M | $3.1M |
| R&D | $13.9M | $12.4M | $11.7M | $10.9M | $9.3M | $4.7M | $2.8M | $2.3M | $2.8M | $2.6M |
| SG&A | $16.5M | $12.0M | $11.8M | $9.6M | $8.0M | $5.3M | $4.3M | $4.3M | $4.0M | $4.2M |
| Operating income | -$24.2M | -$19.7M | -$22.4M | -$16.3M | -$13.4M | -$6.2M | -$4.6M | -$5.2M | -$6.3M | -$7.5M |
| Interest expense | $2.4M | $518.0K | $386.0K | $81.0K | $973.0K | $1.4M | $955.0K | $980.4K | $872.9K | $1.1M |
| Pre-tax income | -$25.5M | -$18.9M | -$22.1M | -$16.4M | -$14.4M | -$6.8M | — | — | — | — |
| Income tax | $55.0K | $12.0K | $8.0K | $0 | $0 | $0 | — | — | — | — |
| Net income | -$25.5M | -$18.9M | -$22.1M | -$16.4M | -$14.4M | -$6.8M | -$5.5M | -$6.2M | -$7.2M | -$8.1M |
| EPS, basic | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | — | — | — | — | — |
| EPS, diluted | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | -0.43 | -0.42 | -0.56 | -0.93 | -2.93 |
| Shares, diluted (wtd. avg.) | $28.3M | $27.0M | $24.6M | $24.2M | $20.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.9M | $20.1M | $23.1M | $27.6M | $54.1M | $20.1M | $5.7M | $3.1M | $9.3M | $3.3M |
| Short-term investments | — | — | $0 | $9.9M | $0 | — | — | — | — | — |
| Receivables | $6.5M | $4.7M | $3.2M | $2.7M | $2.3M | $1.9M | $1.1M | $1.2M | $949.4K | $865.9K |
| Inventory | $8.4M | $6.9M | $7.9M | $9.3M | $4.9M | $3.2M | $3.2M | $2.1M | $2.3M | $1.8M |
| Total current assets | $63.6M | $33.4M | $36.2M | $51.2M | $61.9M | $25.5M | $10.4M | $6.7M | $12.7M | $6.1M |
| Property, plant and equipment | $2.6M | $2.0M | $1.4M | $806.0K | $539.0K | $319.0K | $447.0K | $377.7K | $267.7K | $328.2K |
| Goodwill | $7.5M | $0 | — | — | — | — | — | — | — | — |
| Other intangibles | $13.9M | $0 | — | — | — | — | — | — | — | — |
| Total assets | $97.7M | $39.2M | $42.7M | $55.5M | $65.6M | $29.5M | $11.9M | $7.9M | $13.9M | $7.4M |
| Accounts payable | $1.3M | $1.3M | $393.0K | $272.0K | $427.0K | $300.0K | $966.0K | $500.9K | $759.4K | $1.5M |
| Total current liabilities | $10.8M | $10.4M | $7.4M | $6.8M | $4.8M | $3.2M | $3.8M | $1.9M | $4.4M | $3.0M |
| Long-term debt | $49.1M | — | $9.9M | $9.9M | $9.8M | $21.3M | $2.1M | $3.5M | $4.9M | $4.5M |
| Total liabilities | $69.7M | $13.8M | $21.5M | $18.6M | $16.8M | $27.1M | $7.3M | $6.3M | $8.1M | $8.2M |
| Retained earnings | -$216.9M | -$191.4M | -$172.5M | -$150.4M | -$133.9M | -$119.5M | -$112.7M | -$107.2M | -$101.0M | -$93.9M |
| Total equity | $28.0M | $25.4M | $21.2M | $36.9M | $48.8M | $2.4M | $4.6M | $1.5M | $5.8M | -$756.1K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.9M | -$8.9M | -$13.7M | -$16.2M | -$12.7M | -$7.8M | -$2.9M | -$4.6M | -$6.0M | -$5.8M |
| Depreciation and amortisation | $814.0K | $980.0K | $626.0K | $244.0K | $159.0K | $334.0K | $144.0K | $109.4K | $116.5K | $155.7K |
| Stock-based compensation | $8.2M | $6.9M | $6.1M | $4.1M | $2.1M | $1.1M | $799.0K | $1.2M | $1.2M | $1.2M |
| Capital expenditure | $522.0K | $275.0K | $717.0K | $253.0K | $168.0K | $41.0K | $10.0K | $63.5K | $26.8K | $101.0K |
| Investing cash flow | $615.0K | -$275.0K | $8.9M | -$10.7M | -$168.0K | -$482.0K | -$160.0K | -$63.5K | -$26.8K | -$101.0K |
| Financing cash flow | $50.2M | $6.2M | $296.0K | $409.0K | $46.9M | $22.7M | $5.6M | -$1.5M | $12.0M | $3.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-151345.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |